Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ravi Vij

Showing results (131-140 of 283) with videos related to

Pageof 29
Sort By:
American Journal of Hematology|August 5, 2011
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I studyJohn S Welch, Jeffery M Klco, Feng Gao, et al.
Scientific Reports|January 8, 2022
Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survivalDeep Hathi, Chantiya Chanswangphuwana, Nicholas Cho, et al.
Leukemia & Lymphoma|May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaShaji Kumar, Brian Durie, Hareth Nahi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 26, 2014
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancyMary Eapen, Brent R Logan, Fredrick R Appelbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin LymphomaPavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic SyndromeIskra Pusic, Jaebok Choi, Mark A Fiala, et al.
American Journal of Hematology|September 3, 2015
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myelomaShaji K Kumar, Amrita Krishnan, Betsy LaPlant, et al.
Leukemia & Lymphoma|May 14, 2013
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomideTzu-Fei Wang, Rohan Ahluwalia, Mark A Fiala, et al.
American Journal of Hematology|June 12, 2016
Proteasome inhibitor associated thrombotic microangiopathyJennifer C Yui, Jan Van Keer, Brendan M Weiss, et al.
Haematologica|July 23, 2016
Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamideScott R Goldsmith, Michael Slade, John F DiPersio, et al.
Pageof 29

Showing results (131-140 of 283) with videos related to

Sort By:
Pageof 29
American Journal of Hematology|August 5, 2011
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I studyJohn S Welch, Jeffery M Klco, Feng Gao, et al.
Scientific Reports|January 8, 2022
Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survivalDeep Hathi, Chantiya Chanswangphuwana, Nicholas Cho, et al.
Leukemia & Lymphoma|May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaShaji Kumar, Brian Durie, Hareth Nahi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 26, 2014
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancyMary Eapen, Brent R Logan, Fredrick R Appelbaum, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 12, 2017
Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin LymphomaPavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 10, 2015
Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic SyndromeIskra Pusic, Jaebok Choi, Mark A Fiala, et al.
American Journal of Hematology|September 3, 2015
Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myelomaShaji K Kumar, Amrita Krishnan, Betsy LaPlant, et al.
Leukemia & Lymphoma|May 14, 2013
The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomideTzu-Fei Wang, Rohan Ahluwalia, Mark A Fiala, et al.
American Journal of Hematology|June 12, 2016
Proteasome inhibitor associated thrombotic microangiopathyJennifer C Yui, Jan Van Keer, Brendan M Weiss, et al.
Haematologica|July 23, 2016
Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamideScott R Goldsmith, Michael Slade, John F DiPersio, et al.
Pageof 29